GOLDEN, Colo., Feb. 24 /PRNewswire/ -- CeMines(TM) Inc., a life sciences company specializing in molecular research and development of minimally invasive clinical diagnostics and bioinformatics-based applications for targeted cancer therapeutics, today announced that the Company has been selected to make a poster presentation on Friday, Feb. 25, 2005, at the American Association for Cancer Research (AACR) Special Conference on Molecular Pathogenesis of Lung Cancer: "Opportunities for Translation to the Clinic."
The poster is titled: "Peptide Epitopes in Lung Cancer Diagnostics", presented by Mehis Pold, M.D. It is a result of collaborative work done by CeMines with partners at Karolinska Institutet, Sweden, National Institute for Health Development, Estonia and UCLA, USA.
"A number of diseases, including cancer, can be characterized by changes in autoantibody patterns. Our research has focused the detection of autoantibodies in lung cancer patients, using epitope microarrays," explained Dr. Toomas Neuman, CeMines' chief scientific officer. "Our poster describes our study of serum samples from lung cancer patients and control patients. We have identified autoantibody patterns that are characteristic for lung cancer and are able to discriminate between lung cancer patients and individuals with no cancer with very high accuracy and substantially lower false indications. Epitope microarrays will be used in our first blood-based cancer diagnostic product, CellCorrect(TM) Lung Cancer Diagnostic Kit. It is the Company's goal to pursue commercialization of a series of these blood-based cancer diagnostic arrays which are minimally invasive, cost-effective, cancer diagnostic tools."
The poster presentation will be made by Mehis Pold, M.D., CeMines' Director of Research, Molecular Medicine. Prior to joining CeMines in September 2004, Dr. Pold had been a researcher in the Division of Pulmonology at UCLA's David Geffen School of Medicine, where he played a leading role in two successful cancer-genomics-based studies explaining the role of the well- recognized inflammation modulator cyclooxygenase-2 (COX-2) in lung cancer.
CeMines(TM) Inc., a life sciences company specializing in molecular research, is developing minimally invasive clinical diagnostic tests and targeted therapeutics for cancer. CeMines' novel approach to understanding human cellular regulatory mechanisms resulted in the discovery of CeMines Molecular FingerPrinting(TM), a patent-pending bioinformatics process for identification and profiling of cancer cells. CeMines' headquarters is in Golden, Colorado: http://www.cemines.com/.
CONTACT: Ronald Trahan, APR, of Ronald Trahan Associates Inc.,+1-781-762-9782, ext. 18